A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study.
about
Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancerPegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancerPegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trialsTreatment options in recurrent ovarian cancer: latest evidence and clinical potential.The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trialsA Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.Pegylated liposomal doxorubicin in the management of ovarian cancerPhase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer.Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients.A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?Carboplatin and Liposomal Doxorubicin for Ovarian Cancer.A network meta-analysis of eight chemotherapy regimens for treatment of advanced ovarian cancer.Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts.Use of pattern recognition analysis to identify underlying relationships of Doxorubicin derivatives optimized for breast cancer treatment.Efficacy and safety of traditional chemotherapies for patients with ovarian neoplasm: a network meta-analysis
P2860
Q24198096-F7D28F92-D934-415E-8D4B-7E2711BE1CFDQ24202975-7DAD21E5-45C1-431D-B2CB-21B6B4DA3686Q26858830-28C8C30E-3838-45E9-9163-FB7B36FB7E7AQ27692699-A493373F-8847-4846-A755-3EBC7FEB2D5CQ33409319-3D746FCC-7D00-4309-90D5-0E822209A98FQ33420283-C7F1C4AA-30F3-442E-8324-1215EBD280F5Q34187661-5E30A905-2C27-4C52-A6D8-13A6E614B284Q35653739-5C4D00C3-0A64-4CDC-BA2B-C8BDADBE6407Q36166812-F04893C0-A200-44A0-9105-9EC78AE2CA6FQ36689744-F7E186AB-71BF-4EBA-B6C7-7866C68903CCQ37016053-B820BBB8-AAA6-493C-B137-B69583772E8BQ37745944-2B665BDB-039B-44D1-863B-824A7420B2B6Q37965631-BAD0B277-7658-43FF-A9F7-571663BB6B30Q38738908-F4C26C31-CBB8-4336-A5C5-2E021073A569Q41709594-8CDF2056-8A74-46D9-9EFF-77E00C8C7D1B
P2860
A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A randomized phase II study of ...... perative Oncology Group study.
@ast
A randomized phase II study of ...... perative Oncology Group study.
@en
type
label
A randomized phase II study of ...... perative Oncology Group study.
@ast
A randomized phase II study of ...... perative Oncology Group study.
@en
prefLabel
A randomized phase II study of ...... perative Oncology Group study.
@ast
A randomized phase II study of ...... perative Oncology Group study.
@en
P2093
P2860
P356
P1433
P1476
A randomized phase II study of ...... operative Oncology Group study
@en
P2093
Aristotelis Bamias
Christos Christodoulou
Christos Papadimitriou
Dimitrios Bafaloukos
Dimitrios Pectasides
Eleni Timotheadou
Epaminondas Samantas
Evangelos Briasoulis
George Fountzilas
Gerasimos Aravantinos
P2860
P2888
P356
10.1186/1741-7015-8-3
P407
P577
2010-01-07T00:00:00Z
P5875
P6179
1023692393